Risk factor
Low price volatility
Profitability factor
Overvalued vs peers
About
Sandoz Group AG, headquartered in Rotkreuz, Switzerland, and established in 1886, operates globally in the pharmaceutical sector. The company focuses on the development, production, and commercialization of generic medicines and biosimilars. Beyond this, Sandoz supplies finished dosage forms of small-molecule drugs to third parties. Its portfolio also encompasses protein-based and other biotechnological products, alongside providing biotechnology manufacturing services. A significant aspect of its operations involves anti-infectives, specifically active pharmaceutical ingredients and intermediates, primarily for antibiotics.
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers. In particular, the stock is reasonably priced on P/E, of fair value on EV/EBITDA,
Target Price
The average target price of SDZ.SW is 71.0 and suggests 0.481% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommenda